Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581421 | 1.00 | TSHR (0.61) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL11672299 | 1.00 | TSHR (0.61) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL1983908 | 1.00 | TSHR (0.61) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL1982599 | 1.00 | TSHR (0.61) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL1982870 | 1.00 | TSHR (0.61) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL11674143 | 1.00 | TSHR (0.61) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL4580407 | 0.98 | TSHR (0.63) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL4578754 | 0.93 | TSHR (0.63) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL28009667 | 0.92 | TSHR (0.53) | TSHRALDH1A1CYP3A4DNM1POLB | |
| SCHEMBL9337209 | 0.92 | TSHR (0.53) | TSHRALDH1A1CYP3A4DNM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4194523-A1 | CYANOACRYLATE ADHESIVE COMPOSITION | Cuantum Medical Cosmetics, S.L. (ES) | 2023-06-14 | — | — | EP | claimed |
| EP-4194523-A1 | CYANOACRYLATE ADHESIVE COMPOSITION | Cuantum Medical Cosmetics, S.L. (ES) | 2023-06-14 | — | — | EP | disclosed |
| US-7341716-B2 | Occlusive composition | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1494999-B1 | OCCLUSIVE COMPOSITION COMPRISING A POLY(2-CYANOACRYLATE) MONOMER | BOSTON SCIENT LTD (BB) | 2006-06-07 | — | — | EP | disclosed |
| EP-1494999-A1 | OCCLUSIVE COMPOSITION COMPRISING A POLY(2-CYANOACRYLATE) MONOMER | Boston Scientific Limited (BB) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087042-A1 | OCCLUSIVE COMPOSITION COMPRISING A POLY (2-CYANOACRYLATE) MONOMER | BOSTON SCIENTIFIC LIMITED (BB) | 2003-10-23 | — | — | WO | disclosed |
| US-20030194389-A1 | Occlusive composition | STRYKER CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-4041062-A | CROSSLINKING AGENTS FOR DENTAL ADHESIVE, SEALING OR COATING POLYMERS | JOHNSON & JOHNSON (US) | 1977-08-09 | — | — | US | disclosed |
| US-4041063-A | CROSSLINKING AGENTS FOR DENTAL ADHESIVE, SEALING OR COATING POLYMERS | JOHNSON & JOHNSON (US) | 1977-08-09 | — | — | US | disclosed |
| US-4041061-A | CROSSLINKING AGENTS FOR DENTAL ADHESIVE, SEALING OR COATING POLYMERS | JOHNSON & JOHNSON (US) | 1977-08-09 | — | — | US | disclosed |
| US-4013703-A | CROSSLINKING AGENTS; MONOMERS FOR ADHESIVE POLYMERS | JOHNSON & JOHNSON (US) | 1977-03-22 | — | — | US | disclosed |
| US-4012402-A | Modified cyanoacrylate monomers and methods for preparation | JOHNSON & JOHNSON (US) | 1977-03-15 | — | — | US | disclosed |
| US-4003942-A | CROSSLINKING AGENTS; DENTAL ADHESIVES | JOHNSON & JOHNSON (US) | 1977-01-18 | — | — | US | disclosed |
| US-3975422-A | Preparation of bis (2-cyanoacrylate)monomers | JOHNSON & JOHNSON (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194389-A1 | Occlusive composition | C3AR1, F12, FGB | TSHR 3434/4885ALDH1A1 1135/4885CYP3A4 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.